Press "Enter" to skip to content

Morning Break: Another Ebola Center Attack; 23andMe for T2D; Dr. Death Robot

Note that some links may require subscriptions.

Another Ebola treatment center in the Democratic Republic of the Congo was attacked, killing one police officer and injuring several health workers. (AP)

Esketamine, the newly-approved, fast-acting depression treatment, may come with its own host of challenges including logistical issues and cost. (New York Times)

23andMe said it will offer a new service telling customers “how their DNA affects their chances of developing type 2 diabetes,” and endocrinologists were cautiously supportive. (STAT)

Speaking of diabetes, will Eli Lilly’s half-price insulin really help patients? NPR investigates.

Healthcare employment continues to increase, as indicated by the Bureau of Labor Statistics’ monthly job numbers.

In the past 12 months, 236 confirmed or probable cases of mumps have been reported among immigrants in detention facilities. (Reuters)

Single-payer health care: panacea or pipe dream? (KevinMD)

CNBC explains why FDA Commissioner Gottlieb’s departure might not be great for the vaping industry after all.

Meet the behaviorist behind the common child disciplinary tactic, the “timeout.” (Washington Post)

CVS is in the process of “updating” its on-hold music, much to the delight of one child psychiatrist in Massachusetts. (Fox News)

A patient’s family was horrified when a doctor delivered a “grim prognosis” via a video screen on a robot. (CNN)

Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]

2019-03-11T09:00:00-0400

Source: MedicalNewsToday.com